Table of Contents Table of Contents
Previous Page  92 / 94 Next Page
Information
Show Menu
Previous Page 92 / 94 Next Page
Page Background

90

NCCN Guidelines for Patients

®

:

Acute Lymphoblastic Leukemia, Version 1.2017

Index

Index

adolescent and young adult (AYA)

28, 34, 43,

45–49, 54–57, 68, 76

BCR-ABL

gene

36, 65, 83

bone marrow

6, 8–9, 11–12, 15–16, 18–19, 21,

23–25, 34–35, 37, 39–41, 43, 46–47, 50–51, 53–55,

58–59, 63–64

bone marrow aspiration

18, 63–64

bone marrow biopsy

18, 25

central nervous system (CNS)

34–35, 40, 43, 46,

49–50, 53–54, 57–58, 61–62, 64, 66–67

chemotherapy

15–16, 32–36, 38–43, 46–62, 65–68

chromosome

10, 19–21, 25, 27–29, 36, 45–46, 48,

51–52, 56–57, 61, 65, 67

clinical trial

31–32, 42–43, 45–46, 50–51, 54, 58–59,

65–66, 67–68, 72

consolidation

35, 40, 43, 47–49, 51–53, 55–57,

59–63

follow-up

44, 49, 56–57, 60–64

imaging test

23–24, 64

induction

35, 37, 46–59, 61–63, 65–68

intrathecal (IT) chemotherapy

35, 46, 50, 54, 58

lumbar puncture

15, 22, 35, 46, 50, 54, 58, 63–64

maintenance

34–35, 43, 48–49, 52–53, 56–57,

60–63

multidisciplinary team

45

older adult

28–29, 34, 45, 50–53, 58–62, 66, 68

Philadelphia chromosome

20–21, 27–29, 36,

45–46, 51, 65, 67

protocol

34, 54

refractory

37, 46–47, 50–51, 54–55, 59, 65–68

regimen

32–34, 36, 38, 43, 46–63, 65–68

relapse

37, 46, 49–50, 53–54, 57–58, 62–68

remission

35, 37, 46–62, 65, 67–68

response

36–37, 47, 50–51, 54–55, 58–59, 65, 67

side effect

16, 28, 31, 34–35, 38–43, 48–49, 51–53,

56–57, 59, 61–62, 66–68

stem cell transplant (SCT)

16, 34, 39–40, 48–49,

52–53, 56–57, 60–62, 66–68

subtype

27–29, 36, 45, 48, 52, 56, 61

targeted therapy

36–38, 43, 46, 51, 68

tyrosine kinase inhibitor (TKI)

36, 38, 46, 48–53,

65–66